Cerebral Proliferative Angiopathy: An Uncommon and Misdiagnosed Entity

Sarbesh Tiwari1  Pawan K. Garg1  Pushpinder S. Khera1  Santhosh Babu1  Binit Sureka1  Taruna Yadav1

1Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Basni, Jodhpur, Rajasthan, India

Address for correspondence Pawan Kumar Garg, MD, Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Basni, Jodhpur 342005, Rajasthan, India (e-mail: drgargpawan@gmail.com).

Abstract
Cerebral proliferative angiopathy (CPA), previously known as diffuse nidus-type arteriovenous malformation (AVM) is an entity distinct from cerebral AVM, characterized by multiple small arterial feeders, large-size nidus involving entire lobe or hemisphere, and no early draining veins with normal brain parenchyma interspersed between the abnormal vessels. It is usually seen in younger age group and is more common in females. We hereby report a case of diffuse cerebral proliferative angiopathy in a 29-year-old man who presented with intracranial hemorrhage. It is important to recognize this entity to avoid aggressive treatment, thus preventing permanent damage to the normal intermingled brain tissue.

Keywords
► cerebral proliferative angiopathy
► arteriovenous malformation

DOI https://doi.org/10.1055/s-0039-3401329
ISSN 2457-0214.

©2020 by Indian Society of Vascular and Interventional Radiology

Introduction
Cerebral proliferative angiopathy (CPA) is a type of vascular malformation of brain with symptoms and imaging appearance similar to arteriovenous malformation (AVM). However, multiple features help in diagnosis of CPA on digital subtraction angiography (DSA) including diffuse network of vessels with intermingled normal brain parenchyma, large nidus size, no or minimal hypertrophy of feeding arteries, absence of flow-related aneurysms, absence of large draining vein, and diffuse angiogenesis.

Case Report
A 29-year-old man presented to neurosurgery outpatient department (OPD) of an outside hospital with chronic unsteadiness of gait with sudden onset of headache and weakness in right upper and lower limb. His Glasgow Coma Scale (GCS) score was 15/15 at the time of presentation. There was no history of hypertension or diabetes. Other laboratory investigations were unremarkable. Noncontrast computed tomography (NCCT) (►Fig. 1A, B) brain revealed small amount of intraventricular hemorrhage with some hyperdense vascular channels in left temporal lobe. Considering possibility of vascular malformation, computed tomography (CT) angiography of brain was performed using 50 mL intravenous contrast iohexol (Contrapaque, J.B. Chemicals) on a 256-slice dual-source CT scanner (Siemens Somatom Flash, Siemens GmBH) which revealed an abnormal tangle of vessels in left temporal lobe consistent with a nidus of AVM being supplied by branches of left middle and posterior cerebral arteries; however, no hypertrophy of feeder arteries was noted. (►Fig. 1C).

Considering the possibility of a large ruptured cerebral AVM a digital subtraction angiography (DSA) of cerebrovascular arteries was performed for further characterization, to get dynamic information and to look for risk factors like intranidal aneurysm and venous sac. The study was performed under local anesthesia through right transfemoral route on a biplane DSA machine (Allura Clarity FD 20/20, Philips) using iohexol as intravenous (IV) contrast. A 5-Fr, 11-cm angiography sheath (Cook Medical) was placed in the right femoral artery after accessing the artery under fluoroscopic guidance using a 18 G puncture needle (Cook Medical). Selective angiographic runs were obtained using a 5-Fr H1 diagnostic catheter (Cook Medical) for bilateral internal carotid arteries (ICA), external carotid arteries (ECA) and vertebral arteries.

Left ICA angiogram (►Fig. 2A, B) revealed a large sized diffuse nidus involving the entire left temporal lobe being supplied by multiple small branches of left middle cerebral arteries with no significant arterial hypertrophy. The nidus was also supplied
by small branches of left posterior cerebral artery. Transdural feeders from left ECA branches (►Fig. 2C) were also seen to be supplying the nidus. No intranidal aneurysms or venous sac and early draining vein were identified. Considering all these features a possibility of CPA was thought of and further magnetic resonance imaging (MRI) with perfusion study was performed.

MRI brain was performed on a 3 Tesla scanner (Discovery HD, General Electric, Milwaukee, United States). MRI brain T1W (►Fig. 3A) and angiography (►Fig. 3B) reveal tangles of vessels in left temporal lobe with normal interspersed brain parenchyma. MR perfusion (►Fig. 3C) performed which reveal increased cerebral blood volume (CBV) in nidus. The CBV is decreased in parenchyma around the nidus. These features further favor a diagnosis of CPA, since its etiology is thought to be due to abnormal angiogenesis in response to cortical ischemia and widespread hypoperfusion.

As there is normal interspersed brain parenchyma, aggressive treatment in form of endovascular embolization,
radiotherapy or surgery was not advised, since literature review suggested that it might lead to loss of blood supply to interspersed brain parenchyma leading to ischemia and worsening of symptoms. Patient was advised medical management with antiepileptics and regular imaging follow-up.

Discussion

Vascular lesions or malformations of brain include a wide variety of disorders with overlapping imaging and clinical features. The commonest classification system divides vascular lesions into AVM, which may be either pial or dural (depending on the location of the shunt); cavernous hemangiomas (or cavernomas); capillary telangiectasias; and developmental venous anomalies (DVs, formerly known as venous angiomas).1

Cerebral proliferative angiopathy (CPA), previously known as diffuse nidus type arteriovenous malformation (AVM)? CPA is a distinct entity different from cerebral AVM in angioarchitecture, natural history, clinical presentation, and, therefore, treatment options.2 It is characterized by a diffuse network of vessels with intermingled normal brain parenchyma. Large size of the nidus and the small shunting volume, no or minimal hypertrophy of feeding arteries, absence of flow-related aneurysms, absence of large draining vein and venous sac, diffuse angiogenesis (e.g., transdural supply, progressive arterial occlusion) are the angiographic hallmarks of this disease.1–3 Parenchymal involvement often involves an entire lobe or even a hemisphere with the nidus fed by multiple normal or moderately enlarged arteries and associated stenosis of feeder arteries.2,3

Patients with this disease present with intractable seizures, motor deficits, headaches and stroke like symptoms. Hemorrhage is relatively uncommon.1,4 However, in patients complicated with bleeding, the estimated risk of rebleeding is high (67%).4 This condition most commonly affects women of young age group, in a ratio of 2:1 and is reported as a rare entity. It corresponds to 3.4% of all cerebral arteriovenous malformations.1,5,6

CT or MRI usually shows diffuse vascular lesions with interspersed normal brain parenchyma. MR perfusion is helpful, it shows increased cerebral blood volume (CBV) and only slightly decreased time to peak (TTP) and a prolonged mean transit time (MTT) in the nidus. Regions of increased TTP values and decreased CBV located remote from the nidus, in both cortical and subcortical areas are indicative of remote and widespread hypoperfusion.1

This cerebral hypoperfusion in CPA is evaluable by using N-isopropyl-p-[123I]iodoamphetamine single-photon emission computed tomography (123I-IMP-SPECT). 123I-IMP-SPECT at resting state shows preserved uptake within the vascular lesion, yet lower uptake in the area adjacent to the lesion suggests cerebral ischemia.7

DSA is gold standard for diagnosis of CPA due to its real-time dynamic flow evaluation capability. The DSA generally shows a nidus size greater than 6 cm with venous drainage not having ectasia, in most cases.8

If histopathology is done, the lesion shows abnormal arteries and veins with altered lamination of the internal elastic lamina and muscle fibers on the arterial site and collagenous thickening of the veins.1

Due to presence of viable cerebral parenchyma interspersed between the tangled nidus, attempts to treat these patient by any measure like surgery, embolization, or radiotherapy can aggravate the neurological deficits. However, therapeutic management is indicated in extreme cases, such as intractable epileptic seizures although with great risks of aggravating neurological deficits. Since the pathomechanism is ischemia-induced angiogenesis, successful treatment with pial synangiosis or burr-hole therapy to enhance supply to healthy brain tissue from the external carotid artery are suggested (similar to Moyamoya disease).1,9 Encephaloduroarteriosynangiosis (EDAS) has been described to improve symptoms in adult CPA with cerebral ischemia in which neurologic deficits.9

Evidence of ongoing angiogenesis with elevated levels of vascular endothelial growth factor (VEGF) basic fibroblast growth factor in CSF has been described in patients with CPA; however, it is currently not clear if treatment with monoclonal antibody against VEGF could be of benefit.5,10

Conclusion

Cerebral proliferative angiopathy is a rare distinct entity which should be differentiated from classic cerebral AVM. Aggressive therapeutic treatment in the form of endovascular embolization, surgery, or radiotherapy may lead to permanent brain parenchymal damage and aggravate neurological deficits. Since the pathomechanism of CPA is ischemia-induced angiogenesis, treatment in the form of pial synangiosis or burr-hole therapy may be successful. In future monoclonal antibody against various growth factors may be useful to treat CPA.

Source(s) of Support
None.

Presentation at a Meeting
None.

Conflicts of Interest
None.

Acknowledgments
None.

References

5 Gold JJ, Crawford JR. Acute hemiparesis in a child as a presenting symptom of hemispheric cerebral proliferative angiopathy. Case Rep Neurol Med 2013;2013:920859